CORT · 10-Q

[AI summary · GPT 4o mini · full]

Executive summary Corcept Therapeutics (CORT) reported strong Q2 2026 financial results with significant revenue growth, driven by the launch of Lifyorli™. However, a decline in current assets raises liquidity concerns, compounded by ongoing legal challenges that could impact future performance.

What matters - Product Revenue Growth: Q2 2026 product revenue reached $256.1 million, up 31.7% from $194.4 million in Q2 2025, indicating strong market demand. - Net Income Increase: Net income rose to $42.9 million from $35.1 million year-over-year, reflecting effective cost management despite rising operating expenses. - Liquidity Concerns: Current assets fell to $439.7 million from $485.5 million, primarily due to a $54.5 million drop in short-term marketable securities, signaling potential cash flow issues. - FDA Approval: Lifyorli™ was approved in March 2026 for treating platinum-resistant ovarian cancer, enhancing revenue potential and expanding the product portfolio. - Legal Risks: A newly filed securities class action and ongoing patent litigations, including a ruling favoring Teva's generic version of Korlym, pose significant risks to financial stability and market position.

What's new vs context - Lifyorli™ Launch: The approval and subsequent sales of Lifyorli™ represent a new revenue stream since the last filing. - Legal Developments: The filing of a securities class action and the appellate court ruling on Teva's generic Korlym are new risks that were not present in prior filings. - Cash Position: The decrease in cash and marketable securities is a notable change from previous filings, indicating a shift in liquidity status.

Risks & open questions - Monitor cash flow trends in relation to rising operating expenses and revenue growth. - Watch for updates on the FDA review of relacorilant, with a target date of December 17, 2026. - Keep an eye on the outcomes of ongoing legal challenges, particularly the securities class action and antitrust litigation. - Assess the market response to Lifyorli™ sales and its impact on overall revenue.

Bottom line Investors should remain cautious due to liquidity concerns and legal risks, while also recognizing the potential upside from Lifyorli™'s market performance. Monitoring upcoming financial disclosures and legal developments will be crucial for assessing the investment outlook.